Financials data is unavailable for this security.
View more
Year on year BrightPath Biotherapeutics Co Ltd had revenues fall -98.64% from 5.28m to 72.00k, though the company grew net income from a loss of 1.49bn to a smaller loss of 1.17bn.
Gross margin | 75.00% |
---|---|
Net profit margin | -1,431,842.00% |
Operating margin | -1,421,983.00% |
Return on assets | -108.84% |
---|---|
Return on equity | -123.78% |
Return on investment | -116.51% |
More ▼
Cash flow in JPYView more
In 2024, cash reserves at BrightPath Biotherapeutics Co Ltd fell by 473.61m. Cash Flow from Financing totalled 690.96m or 959,665.28% of revenues. In addition the company used 1.16bn for operations while cash used for investing totalled 7.65m.
Cash flow per share | -18.17 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 9.44 |
---|---|
Tangible book value per share | 9.44 |
More ▼
Balance sheet in JPYView more
Current ratio | 8.78 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼